NASDAQ:AXDX

Accelerate Diagnostics Stock Forecast, Price & News

$5.98
0.00 (0.00 %)
(As of 09/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.81
$6.03
50-Day Range
$5.46
$7.59
52-Week Range
$5.35
$15.60
Volume111,843 shs
Average Volume319,992 shs
Market Capitalization$367.76 million
P/E RatioN/A
Dividend YieldN/A
Beta1.88
30 days | 90 days | 365 days | Advanced Chart
Receive AXDX News and Ratings via Email

Sign-up to receive the latest news and ratings for Accelerate Diagnostics and its competitors with MarketBeat's FREE daily newsletter.


Accelerate Diagnostics logo

About Accelerate Diagnostics

Accelerate Diagnostics, Inc. is an in vitro diagnostics company, which engages in the provision of solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. It also focuses on developing and commercializing innovative instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens. The firm's products include Accelerate Pheno and Accelerate PhenoTest. The company was founded on May 26, 1982 and is headquartered in Tucson, AZ.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.18 out of 5 stars

Medical Sector

366th out of 1,352 stocks

Analytical Instruments Industry

11th out of 30 stocks

Analyst Opinion: 3.3Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Accelerate Diagnostics (NASDAQ:AXDX) Frequently Asked Questions

Is Accelerate Diagnostics a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accelerate Diagnostics in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Accelerate Diagnostics stock.
View analyst ratings for Accelerate Diagnostics
or view top-rated stocks.

What stocks does MarketBeat like better than Accelerate Diagnostics?

Wall Street analysts have given Accelerate Diagnostics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Accelerate Diagnostics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Accelerate Diagnostics' next earnings date?

Accelerate Diagnostics is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Accelerate Diagnostics
.

How were Accelerate Diagnostics' earnings last quarter?

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) released its earnings results on Wednesday, August, 4th. The medical research company reported ($0.36) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.33) by $0.03.
View Accelerate Diagnostics' earnings history
.

How has Accelerate Diagnostics' stock price been impacted by COVID-19?

Accelerate Diagnostics' stock was trading at $10.61 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AXDX shares have decreased by 44.0% and is now trading at $5.94.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for AXDX?

2 analysts have issued 12-month target prices for Accelerate Diagnostics' stock. Their forecasts range from $9.00 to $9.00. On average, they expect Accelerate Diagnostics' stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 51.5% from the stock's current price.
View analysts' price targets for Accelerate Diagnostics
or view top-rated stocks among Wall Street analysts.

Who are Accelerate Diagnostics' key executives?

Accelerate Diagnostics' management team includes the following people:

Who are some of Accelerate Diagnostics' key competitors?

What other stocks do shareholders of Accelerate Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Accelerate Diagnostics investors own include Himax Technologies (HIMX), Magnachip Semiconductor (MX), Fluidigm (FLDM), Universal Display (OLED), Gilead Sciences (GILD), BIOLASE (BIOL), Alibaba Group (BABA), AT&T (T), AbbVie (ABBV) and Micron Technology (MU).

What is Accelerate Diagnostics' stock symbol?

Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."

Who are Accelerate Diagnostics' major shareholders?

Accelerate Diagnostics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (3.81%), Birchview Capital LP (3.66%), Vanguard Group Inc. (2.78%), AXA S.A. (2.68%), Chicago Capital LLC (2.47%) and Cannell Peter B & Co. Inc. (1.79%). Company insiders that own Accelerate Diagnostics stock include Jack Phillips, Jack W Schuler, Romney Humphries, Ron Price and Steven Reichling.
View institutional ownership trends for Accelerate Diagnostics
.

Which institutional investors are selling Accelerate Diagnostics stock?

AXDX stock was sold by a variety of institutional investors in the last quarter, including Rafferty Asset Management LLC, Chicago Capital LLC, BlackRock Inc., Bank of America Corp DE, Millennium Management LLC, Bank of New York Mellon Corp, Wolverine Trading LLC, and Susquehanna International Group LLP. Company insiders that have sold Accelerate Diagnostics company stock in the last year include Jack Phillips, Ron Price, and Steven Reichling.
View insider buying and selling activity for Accelerate Diagnostics
or view top insider-selling stocks.

Which institutional investors are buying Accelerate Diagnostics stock?

AXDX stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Vanguard Group Inc., Nuveen Asset Management LLC, Baird Financial Group Inc., Parametric Portfolio Associates LLC, Geode Capital Management LLC, Group One Trading L.P., and Charles Schwab Investment Management Inc.. Company insiders that have bought Accelerate Diagnostics stock in the last two years include Jack W Schuler, and Steven Reichling.
View insider buying and selling activity for Accelerate Diagnostics
or or view top insider-buying stocks.

How do I buy shares of Accelerate Diagnostics?

Shares of AXDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Accelerate Diagnostics' stock price today?

One share of AXDX stock can currently be purchased for approximately $5.94.

How much money does Accelerate Diagnostics make?

Accelerate Diagnostics has a market capitalization of $365.30 million and generates $11.16 million in revenue each year. The medical research company earns $-78,210,000.00 in net income (profit) each year or ($1.40) on an earnings per share basis.

How many employees does Accelerate Diagnostics have?

Accelerate Diagnostics employs 224 workers across the globe.

What is Accelerate Diagnostics' official website?

The official website for Accelerate Diagnostics is acceleratediagnostics.com.

Where are Accelerate Diagnostics' headquarters?

Accelerate Diagnostics is headquartered at 3950 South Country Club Suite 470, Tucson AZ, 85714.

How can I contact Accelerate Diagnostics?

Accelerate Diagnostics' mailing address is 3950 South Country Club Suite 470, Tucson AZ, 85714. The medical research company can be reached via phone at (520) 365-3100 or via email at [email protected]


This page was last updated on 9/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.